Panacea Bio Chem
Panacea Bio Chem
To understand why oral GLP-1 delivery is so hard, follow one peptide molecule from mouth to bloodstream. It has to survive four barriers in a row, and each one is very good at its job. This is the physiology behind the near-1% ceiling on oral peptide bioavailability.
The stomach runs at roughly pH 1.5–3.5. That acidity, together with the enzyme pepsin, denatures a peptide's folded shape and begins hydrolysing its backbone. A GLP-1 receptor agonist that reached the stomach unprotected would be partly dismantled before it ever moved on. This is exactly the stage the enhancer SNAC targets in oral semaglutide: by raising the local pH right around the tablet, it quietens pepsin long enough for a fraction of the peptide to survive.3
Past the stomach, the small intestine is a protein-digesting machine. Pancreatic trypsin and chymotrypsin, plus a dense fringe of brush-border peptidases on the gut lining, exist to cut dietary protein — and a therapeutic peptide looks exactly like food to them. They cleave the chain into inactive fragments. Nature spent a long time perfecting this; it is why we can eat protein without absorbing it whole.
Even a peptide that survives acid and enzymes meets a thick, continuously renewed mucus gel coating the gut wall. Mucus is a defensive net: it traps particles and large molecules and sweeps them along to be shed, keeping them away from the cells beneath. A liposome or nanoparticle can be caught here before it reaches a single cell.
Finally there is the wall itself: a single sealed sheet of epithelial cells stitched together by tight junctions. To enter the blood, a molecule must either pass through a cell (transcellular) or squeeze between cells (paracellular). A large, water-loving peptide can do neither well: it will not dissolve through a lipid membrane, and the tight junctions seal the gaps. This is the last and highest wall.
To cross that last wall, formulators add intestinal permeation enhancers: SNAC, sodium caprate (C10), bile salts, acylcarnitines and surfactants.2 Broadly they act two ways — paracellular, transiently opening tight junctions (C10, for instance, raises intracellular calcium and loosens the junctional seal), and transcellular, fluidising the cell membrane so the peptide can slip in.
| Enhancer | Primary action | Clinical oral bioavailability |
|---|---|---|
| SNAC (salcaprozate sodium) | Raises local pH; membrane fluidisation; used in oral semaglutide | ~0.4–1% |
| Sodium caprate (C10) | Opens tight junctions (Ca²⁺ / calmodulin); membrane perturbation | ~1% |
An enhancer potent enough to admit a large peptide is non-selective — the same loosened barrier is open to other gut contents while it is open. Reviews of the field note that it is not fully settled how well the epithelium's damage-and-repair keeps pace under chronic daily dosing, and that PE-based programmes have converged on roughly 1% bioavailability rather than a broad leap.2 This is the boundary that led Panacea to set the oral Bioglutide studies aside.
A liposome1 is a lovely carrier — it is why lipid nanoparticles work so well by injection. But orally, the vesicle meets all four barriers in turn: gastric acid and bile can strip or destabilise the lipid shell; digestive lipases and proteases attack shell and cargo; mucus traps the particle; and an intact vesicle still cannot walk through the tight-junction wall on its own. So a nanocarrier ends up needing permeation enhancers too — which means it inherits the same trade-off rather than escaping it. That is the crux of the negative result.
Recent work on the gut barriers & permeation enhancers — refreshed 2026-07-11 by Panacea Bio Chem.